✦ LIBER ✦

Second and third line treatment in non-small cell lung cancer

✍ Scribed by Adolfo Favaretto; Giulia Pasello; Cristina Magro; Clorinda Schettino; Cesare Gridelli

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An update on molecularly targeted therap

✍ Majem, M.; PallarÃ¨s, C. 📂 Article 📅 2013 🏛 Springer Milan 🌐 Spanish ⚖ 460 KB

Second- and third-line treatments in non

✍ Atul Kumar; Heather Wakelee 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 517 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Activity and safety of erlotinib as seco

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

9081 POSTER Network Meta-analysis of Sec

✍ Bianic, F.; Despiegel, N.; Cure, S.; Campbell, J.; Wang, Z.; Cappelleri, J.C.; G 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Second- and Third-line Treatment of Pati

✍ Edward J. Stepanski; Arthur C. Houts; Lee S. Schwartzberg; Mark S. Walker; Carol 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 260 KB